1 Min Read
* Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication
* Biocryst Pharmaceuticals Inc - FDA has approved a supplemental new drug application for Rapivab Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.